- Company
- Generics for Eliquis are sold out
- by Apr 20, 2021 09:13am
- The production and sales of generics that lost Eliquis(Apixaban)' patent dispute were halted. According to the drug distribution industry on the 16th, generic for Eliquis companies stopped producing and selling items at once after the Supreme Court ruling. There is some inventory that has been passed to wholesalers. Generics for Eliquis
- Company
- SG&A ratio fell in 3 out of 4 MNCs...a COVID-19 Impact?
- by An, Kyung-Jin Apr 20, 2021 06:03am
- Korean subsidiaries of multinational pharmaceutical companies have lowered their selling, general & administrative (SG&A) to sales ratio last year due to the prolonged COVID-19 crisis. Analysts predict that the cost-cutting measure was made in response to the disruptions in face-to-face sales and marketing activities caused by the pandemic.
- Company
- Rx drug market recovers after flu season
- by Chon, Seung-Hyun Apr 20, 2021 06:02am
- The outpatient prescription drug market, which was slow in winter, is showing a recovery trend. Since the end of last year, the total prescription drug volume has been on a decline compared to the previous year, but in March it turned to an upward trend. It is analyzed that COVID-19 showed sluggishness due to a sharp decline in infectious diseas
- Company
- Domestic Sputnik V CMO meets with MOHW for discussions
- by Kim, Jin-Gu Apr 20, 2021 06:02am
- With the possibility of using ‘Sputnik V' rising in Korea, various industry sources have confirmed that a Korean CMO of this Russian vaccine has had a meeting with Korea's Ministry of Health and Welfare (MOHW). According to industry officials, one of the companies that signed a CMO deal for Sputnik V has recently had a meeting with a
- Company
- Hemophilia B tx, Benefix, took the lead with weekly therapy
- by Apr 20, 2021 06:02am
- Pfizer Korea's Benefix (nonacog alfa)', which has been used for the treatment of hemophilia B patients in Korea for 15 years, has taken the lead as a once-a-week prophylaxis. The strategy for treating hemophilia has now become routine prophylactic therapy. The World Federation of Hemophilia recommended prophylaxis as standard treatment in
- Company
- Novartis Korea surpassed ₩500 billion in annual sales
- by An, Kyung-Jin Apr 19, 2021 05:55am
- Novartis Korea has surpassed &8361;500 billion in annual sales for the first time since entering Korea. Despite the confusion of COVID-19, representative medicines and new products generated synergy, which led to the highest sales ever. According to the Financial Supervisory Service on the 15th, Novartis Korea last year recorded &8361;532
- Company
- Will ‘Keytruda’ be reviewed for reimbursement in May?
- by Eo, Yun-Ho Apr 16, 2021 06:03am
- MSD Korea threw a game-changer for the reimbursement expansion of the immunotherapy drug ‘Keytruda.’ According to industry sources, the company has once again submitted a revised cost-sharing proposal to the Health Insurance Review & Assessment Service (HIRA) to expand the reimbursement of ‘Keytruda (pembrolizumab)’ to cover first-line tr
- Company
- Celltrion-Icure applied for permission for Donepezil patch
- by Chon, Seung-Hyun Apr 16, 2021 06:02am
- Celltrion announced on the 13th that it has applied to the MFDS for an item license for the “Donerion patch” for the treatment of Alzheimer's dementia jointly developed with Icure. Donerion patch (Donepezil) is a product jointly developed by bio-venture Icure and Celltrion. In June 2017, after Icure developed and completed the non-clinic
- Company
- Vyndamax tries RSA after failing essential drug designation
- by Eo, Yun-Ho Apr 15, 2021 05:56am
- Once again, attempts are in progress to receive reimbursement for 'Vyndamax,' a new drug for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Industry sources said that Pfizer Korea had recently submitted an application for the reimbursement of its new ATTR-CM drug, Vyndamax (tafamidis 61mg). This time, the company condu
- Company
- Measures for the reimbursement of advanced therapies
- by Apr 15, 2021 05:56am
- The release of the CAR-T treatment ‘Kymriah (tisagenlecleucel)’ in Korea was met with both anticipation and concerns. The drug itself is undeniably an innovative drug that can offer new opportunities to blood cancer patients with short life expectancy. However, the challenge lies in how this innovative new drug that costs 500 million won per d
